To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination Program.
作者信息
Wiese Andrew D, Grijalva Carlos G
机构信息
Department of Health Policy, Vanderbilt University Medical Center.
Mid-South Geriatric Research Education and Clinical Center, Veterans Affairs Tennessee Valley Healthcare System, Nashville.
出版信息
Clin Infect Dis. 2020 Jun 10;70(12):2616-2618. doi: 10.1093/cid/ciz735.
Abstract
摘要
相似文献
1
To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination Program.加强接种还是不加强接种？来自澳大利亚肺炎球菌结合疫苗接种计划的经验教训。
Clin Infect Dis. 2020 Jun 10;70(12):2616-2618. doi: 10.1093/cid/ciz735.
2
Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.儿童肺炎球菌结合疫苗对澳大利亚未报告的临床疑似侵袭性肺炎球菌病的影响。
Pediatr Infect Dis J. 2019 Aug;38(8):860-865. doi: 10.1097/INF.0000000000002314.
3
Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.香港地区可通过7价肺炎球菌结合疫苗预防的肺炎球菌疾病导致的儿科住院情况。
Vaccine. 2007 Sep 28;25(39-40):6837-41. doi: 10.1016/j.vaccine.2007.07.039. Epub 2007 Aug 7.
4
Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.澳大利亚 2002-2014 年 7 价和 13 价肺炎球菌结合疫苗“3+0”免疫程序对侵袭性肺炎球菌病的长期影响
Clin Infect Dis. 2017 Jan 15;64(2):175-183. doi: 10.1093/cid/ciw720. Epub 2016 Oct 21.
5
The cost-effectiveness of pneumococcal conjugate vaccination in Australia.澳大利亚肺炎球菌结合疫苗接种的成本效益
Vaccine. 2004 Mar 12;22(9-10):1138-49. doi: 10.1016/j.vaccine.2003.09.036.
6
Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil.估算肺炎球菌结合疫苗在巴西的成本效益。
Rev Panam Salud Publica. 2009 Dec;26(6):518-28. doi: 10.1590/s1020-49892009001200007.
7
Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.肺炎球菌结合疫苗对澳大利亚原住民和非原住民侵袭性疾病和肺炎住院的长期影响。
Clin Infect Dis. 2020 Jun 10;70(12):2607-2615. doi: 10.1093/cid/ciz731.
8
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.13价肺炎球菌结合疫苗（PCV13）在澳大利亚老年人中的成本效益
Vaccine. 2017 Aug 3;35(34):4307-4314. doi: 10.1016/j.vaccine.2017.06.085. Epub 2017 Jul 8.
9
Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia.预防肺炎球菌性社区获得性肺炎的疫苗。
Clin Chest Med. 2018 Dec;39(4):733-752. doi: 10.1016/j.ccm.2018.07.007.
10
Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.引入肺炎球菌结合疫苗后的鼻窦炎和肺炎住院情况。
Pediatrics. 2014 Dec;134(6):e1528-36. doi: 10.1542/peds.2013-4177. Epub 2014 Nov 10.
引用本文的文献
1
Indirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules.在儿科3+1和2+1接种程序中，PCV20与PCV10免疫原性的间接比较
Infect Dis Ther. 2025 May;14(5):1103-1117. doi: 10.1007/s40121-025-01151-0. Epub 2025 Apr 14.
本文引用的文献
1
A Rationale for Change: An Increase in Invasive Pneumococcal Disease in Fully Vaccinated Children.理由变革：完全接种疫苗的儿童侵袭性肺炎球菌病的增加。
Clin Infect Dis. 2020 Feb 3;70(4):680-683. doi: 10.1093/cid/ciz493.
2
Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.肺炎球菌结合疫苗对美国肺炎住院治疗的影响。
Expert Rev Vaccines. 2019 Apr;18(4):327-341. doi: 10.1080/14760584.2019.1582337. Epub 2019 Mar 20.
3
Making sense of differences in pneumococcal serotype replacement.解析肺炎球菌血清型替换中的差异。
Lancet Infect Dis. 2019 Jun;19(6):e213-e220. doi: 10.1016/S1473-3099(18)30660-1. Epub 2019 Jan 29.
4
Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study.7 价和 13 价肺炎球菌结合疫苗在无加强剂量方案中的有效性：一项为期 10 年的观察性研究。
Clin Infect Dis. 2018 Jul 18;67(3):367-374. doi: 10.1093/cid/ciy129.
5
Examining Duration of Protection: Should a Booster Dose Be Part of All Infant Pneumococcal Conjugate Vaccine Programs?研究保护持续时间：加强剂量是否应成为所有婴幼儿肺炎球菌结合疫苗计划的一部分？
Clin Infect Dis. 2018 Jul 18;67(3):375-377. doi: 10.1093/cid/ciy135.
6
Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control.使用复合对照法阐明肺炎球菌结合疫苗计划对英格兰肺炎、败血症和中耳炎住院率的影响。
BMC Med. 2018 Feb 8;16(1):13. doi: 10.1186/s12916-018-1004-z.
7
Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.2000-2017 年期间，英格兰和威尔士导致侵袭性肺炎球菌病的非疫苗血清型快速增加：一项前瞻性全国观察性队列研究。
Lancet Infect Dis. 2018 Apr;18(4):441-451. doi: 10.1016/S1473-3099(18)30052-5. Epub 2018 Jan 26.
8
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.13 价肺炎球菌结合疫苗作为一剂基础免疫和一剂加强免疫（1+1），与两剂基础免疫和一剂加强免疫（2+1）相比，在英国婴儿中的效果：一项多中心、平行组随机对照试验。
Lancet Infect Dis. 2018 Feb;18(2):171-179. doi: 10.1016/S1473-3099(17)30654-0. Epub 2017 Nov 22.
9
Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.澳大利亚 2002-2014 年 7 价和 13 价肺炎球菌结合疫苗“3+0”免疫程序对侵袭性肺炎球菌病的长期影响
Clin Infect Dis. 2017 Jan 15;64(2):175-183. doi: 10.1093/cid/ciw720. Epub 2016 Oct 21.
10
Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis.儿童肺炎球菌结合疫苗间接效应对侵袭性肺炎球菌病的影响：系统评价和荟萃分析。
Lancet Glob Health. 2017 Jan;5(1):e51-e59. doi: 10.1016/S2214-109X(16)30306-0.
Zotero 插件